应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DNTH Dianthus Therapeutics Inc.
未开盘 09-17 16:00:00 EDT
101.12
-1.37
-1.34%
盘后
102.34
+1.22
+1.21%
19:30 EDT
最高
105.85
最低
99.92
成交量
114.06万
今开
104.58
昨收
102.49
日振幅
5.78%
总市值
56.56亿
流通市值
56.48亿
总股本
5,593万
成交额
1.16亿
换手率
2.04%
流通股本
5,585万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Dianthus Therapeutics 披露截至2026年6月30日现金储备达12亿美元,预期运营资金可持续至2030年
美股速递 · 08-05
Dianthus Therapeutics 披露截至2026年6月30日现金储备达12亿美元,预期运营资金可持续至2030年
Dianthus Therapeutics 旗下 Dnth312 靶向抑制 Ac1s 与 Baff/April 通路,布局自身免疫疾病领域
美股速递 · 08-04
Dianthus Therapeutics 旗下 Dnth312 靶向抑制 Ac1s 与 Baff/April 通路,布局自身免疫疾病领域
Dianthus Therapeutics:DNTH312在非人灵长类模型中展现与Povetacicept相当的免疫球蛋白降低效果
美股速递 · 08-04
Dianthus Therapeutics:DNTH312在非人灵长类模型中展现与Povetacicept相当的免疫球蛋白降低效果
异动解读|Dianthus Therapeutics盘中上涨9.22%,报104.14美元
行情直击 · 07-18
异动解读|Dianthus Therapeutics盘中上涨9.22%,报104.14美元
Dianthus Therapeutics预计2026年第四季度公布Momentum试验2期顶线数据,Captivate项目更新将于2026年内完成
美股速递 · 06-29
Dianthus Therapeutics预计2026年第四季度公布Momentum试验2期顶线数据,Captivate项目更新将于2026年内完成
Dianthus Therapeutics宣布启动Claseprubart治疗全身型重症肌无力的III期EMERGE试验
美股速递 · 06-29
Dianthus Therapeutics宣布启动Claseprubart治疗全身型重症肌无力的III期EMERGE试验
Dianthus Therapeutics, Inc.盘中异动 大幅拉升9.52%
市场透视 · 2025-03-05
Dianthus Therapeutics, Inc.盘中异动 大幅拉升9.52%
Dianthus Therapeutics, Inc.盘中异动 早盘快速下挫5.00%报20.52美元
市场透视 · 2025-03-03
Dianthus Therapeutics, Inc.盘中异动 早盘快速下挫5.00%报20.52美元
Dianthus Therapeutics, Inc.盘中异动 临近午盘大幅拉升5.19%
市场透视 · 2025-02-28
Dianthus Therapeutics, Inc.盘中异动 临近午盘大幅拉升5.19%
Dianthus Therapeutics, Inc.盘中异动 早盘急速拉升7.80%
市场透视 · 2025-02-26
Dianthus Therapeutics, Inc.盘中异动 早盘急速拉升7.80%
Dianthus Therapeutics, Inc.盘中异动 早盘快速跳水5.85%报22.29美元
市场透视 · 2025-02-24
Dianthus Therapeutics, Inc.盘中异动 早盘快速跳水5.85%报22.29美元
Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.82%
市场透视 · 2025-02-19
Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.82%
Dianthus Therapeutics, Inc.盘中异动 临近收盘大幅拉升5.00%报24.16美元
市场透视 · 2025-02-14
Dianthus Therapeutics, Inc.盘中异动 临近收盘大幅拉升5.00%报24.16美元
Dianthus Therapeutics, Inc.盘中异动 下午盘股价大跌5.74%
市场透视 · 2025-02-07
Dianthus Therapeutics, Inc.盘中异动 下午盘股价大跌5.74%
Dianthus Therapeutics, Inc.盘中异动 股价大涨5.34%
市场透视 · 2025-02-06
Dianthus Therapeutics, Inc.盘中异动 股价大涨5.34%
Dianthus Therapeutics, Inc.盘中异动 早盘大幅上涨5.03%报22.87美元
市场透视 · 2025-01-31
Dianthus Therapeutics, Inc.盘中异动 早盘大幅上涨5.03%报22.87美元
Dianthus Therapeutics, Inc.盘中异动 早盘大幅上涨5.20%
市场透视 · 2025-01-30
Dianthus Therapeutics, Inc.盘中异动 早盘大幅上涨5.20%
Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.36%报19.97美元
市场透视 · 2025-01-28
Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.36%报19.97美元
Dianthus Therapeutics, Inc.盘中异动 股价大跌5.52%
市场透视 · 2025-01-24
Dianthus Therapeutics, Inc.盘中异动 股价大跌5.52%
Dianthus Therapeutics, Inc.盘中异动 股价大涨5.03%
市场透视 · 2025-01-23
Dianthus Therapeutics, Inc.盘中异动 股价大涨5.03%
加载更多
公司概况
公司名称:
Dianthus Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Dianthus Therapeutics, Inc.于2015年6月17日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司,开发新药,为更多的患者带来骨髓移植的治疗能力。该公司打算成为移植医学领域的完全整合的发现,开发和商业公司。该公司相信产品组合将提供显著的商业协同效应。 该公司正在开发产品,以便可以单独使用或相互结合使用。因此,该公司的投资组合可以以适合患者疾病的方式使用,以便患者可以接受多于一种洋红疗法作为其个人移植旅程的一部分。
发行价格:
--
{"stockData":{"symbol":"DNTH","market":"US","secType":"STK","nameCN":"Dianthus Therapeutics Inc.","latestPrice":101.12,"timestamp":1789675200000,"preClose":102.49,"halted":0,"volume":1140569,"hourTrading":{"tag":"盘后","latestPrice":102.34,"preClose":101.12,"latestTime":"19:30 EDT","volume":113342,"amount":11462159.58,"timestamp":1789687805742,"change":1.22,"changeRate":0.012065,"amplitude":0.012065},"delay":0,"changeRate":-0.013367157771489807,"floatShares":55850100,"shares":55934399,"eps":-4.113023,"marketStatus":"未开盘","change":-1.37,"latestTime":"09-17 16:00:00 EDT","open":104.58,"high":105.845,"low":99.92,"amount":115912879.49956,"amplitude":0.057811,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.113023,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":0,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":102.49,"preHourTrading":{"tag":"盘前","latestPrice":103.4,"preClose":102.49,"latestTime":"09:28 EDT","volume":250,"amount":25903.19,"timestamp":1789651680052,"change":0.91,"changeRate":0.008879,"amplitude":0.005269},"postHourTrading":{"tag":"盘后","latestPrice":102.34,"preClose":101.12,"latestTime":"19:30 EDT","volume":113342,"amount":11462159.58,"timestamp":1789687805742,"change":1.22,"changeRate":0.012065,"amplitude":0.012065},"volumeRatio":1.660372,"impliedVol":0.6035,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/DNTH","defaultTab":"news","newsList":[{"id":"1122665642","title":"Dianthus Therapeutics 披露截至2026年6月30日现金储备达12亿美元,预期运营资金可持续至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1122665642","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122665642?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:37","pubTimestamp":1785875839,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics 最新披露,截至2026年6月30日,公司持有现金储备高达12亿美元。基于当前资金状况,管理层预期这一现金跑道将支持公司运营直至2030年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186641577","title":"Dianthus Therapeutics 旗下 Dnth312 靶向抑制 Ac1s 与 Baff/April 通路,布局自身免疫疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1186641577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186641577?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:11","pubTimestamp":1785841890,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics 公司正着力推进其核心候选药物 Dnth312。该药物旨在通过抑制 Ac1s 以及 Baff/April 这两条关键信号通路,为自身免疫性疾病患者提供全新的治疗策略。此举展现了公司在免疫调节领域的前沿探索与雄心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111288447","title":"Dianthus Therapeutics:DNTH312在非人灵长类模型中展现与Povetacicept相当的免疫球蛋白降低效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1111288447","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111288447?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:11","pubTimestamp":1785841869,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布,其候选药物 DNTH312 在非人灵长类动物(NHPs)研究中,显示出与 Povetacicept 相似的免疫球蛋白降低能力。这一发现表明,DNTH312 在调节免疫反应方面具有潜在的治疗价值。该研究的详细数据尚未完全公布,但初步结果已为后续的临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120010877","title":"异动解读|Dianthus Therapeutics盘中上涨9.22%,报104.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120010877","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120010877?lang=zh_cn&edition=full","pubTime":"2026-07-18 02:51","pubTimestamp":1784314270,"startTime":"0","endTime":"0","summary":"7月18日,Dianthus Therapeutics盘中上涨9.22%,报104.14美元/股,成交额7534.37万美元。Dianthus Therapeutics所在的生物科技行业中,个股中,艾伯维公司涨0.57%,安进跌2.31%,吉利德科学跌1.37%,福泰制药跌0.37%,再生元制药公司跌0.67%。Dianthus Therapeutics是一家临床阶段的生物技术公司,致力于设计和提供新型单克隆抗体,与现有的补体疗法相比,其选择性和效力更高。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154707624","title":"Dianthus Therapeutics预计2026年第四季度公布Momentum试验2期顶线数据,Captivate项目更新将于2026年内完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1154707624","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154707624?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:01","pubTimestamp":1782730911,"startTime":"0","endTime":"0","summary":"生物技术公司Dianthus Therapeutics Inc.近日更新了其关键研发管线的时间表。公司宣布,其备受关注的Momentum试验2期研究的顶线数据预计将在2026年第四季度公布。这项试验是评估其候选疗法在特定适应症中有效性与安全性的重要里程碑。与此同时,公司还透露了另一项名为Captivate的项目的进展。关于Captivate的更新信息预计将在2026年年内完成并对外公布。上述进展预计将对公司的未来发展方向和潜在价值产生重要影响。市场将持续关注Dianthus Therapeutics在这些关键时间点所披露的数据与信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187316053","title":"Dianthus Therapeutics宣布启动Claseprubart治疗全身型重症肌无力的III期EMERGE试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1187316053","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187316053?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:01","pubTimestamp":1782730878,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 已正式启动其候选药物claseprubart用于治疗全身型重症肌无力(gMG)的III期EMERGE临床试验。该试验旨在评估claseprubart在这一自身免疫性神经肌肉疾病中的疗效与安全性,标志着该药物研发进程中的一个关键里程碑。全身型重症肌无力是一种导致肌肉无力和疲劳的慢性疾病,对患者生活质量有显著影响。此次III期试验的启动,是基于先前临床研究获得的积极数据,为潜在的新治疗方案带来了希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517494669","title":"Dianthus Therapeutics, Inc.盘中异动 大幅拉升9.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517494669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517494669?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185055,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分,Dianthus Therapeutics, Inc.股票出现异动,股价急速拉升9.52%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223056abe9b05d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223056abe9b05d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNTH","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516308756","title":"Dianthus Therapeutics, Inc.盘中异动 早盘快速下挫5.00%报20.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516308756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516308756?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:07","pubTimestamp":1741014460,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时07分,Dianthus Therapeutics, Inc.股票出现波动,股价大幅下跌5.00%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.09%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230741989a1a32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230741989a1a32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387469","title":"Dianthus Therapeutics, Inc.盘中异动 临近午盘大幅拉升5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514387469?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:40","pubTimestamp":1740674403,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时40分,Dianthus Therapeutics, Inc.股票出现异动,股价大幅拉升5.19%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.61%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004003abdf8d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004003abdf8d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514566358","title":"Dianthus Therapeutics, Inc.盘中异动 早盘急速拉升7.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514566358?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分,Dianthus Therapeutics, Inc.股票出现异动,股价快速拉升7.80%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.12%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223115abddec78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223115abddec78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNTH","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778530","title":"Dianthus Therapeutics, Inc.盘中异动 早盘快速跳水5.85%报22.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513778530?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:11","pubTimestamp":1740409876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时11分,Dianthus Therapeutics, Inc.股票出现波动,股价急速跳水5.85%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.56%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231116a2521e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231116a2521e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512481862","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512481862?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:51","pubTimestamp":1739980266,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时51分,Dianthus Therapeutics, Inc.股票出现波动,股价快速跳水5.82%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.51%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219235106abd50f87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219235106abd50f87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511815577","title":"Dianthus Therapeutics, Inc.盘中异动 临近收盘大幅拉升5.00%报24.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511815577","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511815577?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:00","pubTimestamp":1739480416,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日05时00分,Dianthus Therapeutics, Inc.股票出现波动,股价急速拉升5.00%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.20%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140500179884777e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140500179884777e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNTH","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509786830","title":"Dianthus Therapeutics, Inc.盘中异动 下午盘股价大跌5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509786830","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509786830?lang=zh_cn&edition=full","pubTime":"2025-02-07 04:11","pubTimestamp":1738872676,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日04时11分,Dianthus Therapeutics, Inc.股票出现波动,股价快速下跌5.74%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.59%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207041116a23c1271&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207041116a23c1271&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNTH","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509231487","title":"Dianthus Therapeutics, Inc.盘中异动 股价大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509231487?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:09","pubTimestamp":1738775373,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时09分,Dianthus Therapeutics, Inc.股票出现波动,股价快速拉升5.34%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.89%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206010934abc39f80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206010934abc39f80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507961840","title":"Dianthus Therapeutics, Inc.盘中异动 早盘大幅上涨5.03%报22.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507961840","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507961840?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:04","pubTimestamp":1738335861,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时04分,Dianthus Therapeutics, Inc.股票出现异动,股价快速上涨5.03%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.27%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312304229614ef31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312304229614ef31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507762499","title":"Dianthus Therapeutics, Inc.盘中异动 早盘大幅上涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507762499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507762499?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:49","pubTimestamp":1738248578,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时49分,Dianthus Therapeutics, Inc.股票出现波动,股价快速拉升5.20%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.28%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224938abbd500e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224938abbd500e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506517828","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.36%报19.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506517828","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506517828?lang=zh_cn&edition=full","pubTime":"2025-01-28 23:11","pubTimestamp":1738077080,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日23时11分,Dianthus Therapeutics, Inc.股票出现异动,股价快速下挫5.36%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.27%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128231120abbb6ef0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128231120abbb6ef0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNTH","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505486257","title":"Dianthus Therapeutics, Inc.盘中异动 股价大跌5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505486257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505486257?lang=zh_cn&edition=full","pubTime":"2025-01-24 23:15","pubTimestamp":1737731752,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日23时15分,Dianthus Therapeutics, Inc.股票出现波动,股价快速下跌5.52%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.49%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012423155398720bc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012423155398720bc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505091705","title":"Dianthus Therapeutics, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505091705","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505091705?lang=zh_cn&edition=full","pubTime":"2025-01-23 04:54","pubTimestamp":1737579294,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日04时54分,Dianthus Therapeutics, Inc.股票出现异动,股价大幅拉升5.03%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.55%。Dianthus Therapeutics, Inc.公司简介:Dianthus Therapeutics Inc 是一家临床阶段生物技术公司,致力于设计和提供新型单克隆抗体,优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123045455a22bffc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123045455a22bffc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.magentatx.com","stockEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.1248},{"period":"3month","weight":0.2258},{"period":"6month","weight":0.3004},{"period":"1year","weight":1.6008},{"period":"ytd","weight":1.4538}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dianthus Therapeutics, Inc.于2015年6月17日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司,开发新药,为更多的患者带来骨髓移植的治疗能力。该公司打算成为移植医学领域的完全整合的发现,开发和商业公司。该公司相信产品组合将提供显著的商业协同效应。 该公司正在开发产品,以便可以单独使用或相互结合使用。因此,该公司的投资组合可以以适合患者疾病的方式使用,以便患者可以接受多于一种洋红疗法作为其个人移植旅程的一部分。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.175283},{"month":2,"riseRate":0.625,"avgChangeRate":0.224994},{"month":3,"riseRate":0.5,"avgChangeRate":0.049298},{"month":4,"riseRate":0.375,"avgChangeRate":-0.05024},{"month":5,"riseRate":0.625,"avgChangeRate":-0.041628},{"month":6,"riseRate":0.75,"avgChangeRate":0.021233},{"month":7,"riseRate":0.666667,"avgChangeRate":0.038404},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.011974},{"month":9,"riseRate":0.333333,"avgChangeRate":0.045074},{"month":10,"riseRate":0.25,"avgChangeRate":-0.093611},{"month":11,"riseRate":0.5,"avgChangeRate":0.042669},{"month":12,"riseRate":0.25,"avgChangeRate":-0.158671}],"exchange":"NASDAQ","name":"Dianthus Therapeutics Inc.","nameEN":"Dianthus Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Dianthus Therapeutics Inc.(DNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Dianthus Therapeutics Inc.,DNTH,Dianthus Therapeutics Inc.股票,Dianthus Therapeutics Inc.股票老虎,Dianthus Therapeutics Inc.股票老虎国际,Dianthus Therapeutics Inc.行情,Dianthus Therapeutics Inc.股票行情,Dianthus Therapeutics Inc.股价,Dianthus Therapeutics Inc.股市,Dianthus Therapeutics Inc.股票价格,Dianthus Therapeutics Inc.股票交易,Dianthus Therapeutics Inc.股票购买,Dianthus Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Dianthus Therapeutics Inc.(DNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}